Johanna Benesty

Johanna Benesty is a core member of Boston Consulting Group’s Health Care and People & Organization and Social Impact practices.

Since joining BCG in 2007, Johanna has worked with leading health care companies on a wide range of strategic and operational issues, such as defining the go-to-market models for specific vaccines, developing strategies for generics, and defining generic-drug portfolios for emerging markets. She has also helped health care clients plan and execute a number of large-scale transformation initiatives.

In addition, Johanna has extensive experience partnering with social impact organizations dedicated to improving public health. Her work has included providing input on the World Health Organization’s HIV drug-resistance surveillance strategy; supporting the Global Fund to fight AIDS, Tuberculosis, and Malaria in developing partnerships with technical agencies; and assisting the WHO, United Nations, and Partnership for Maternal and Child Health in writing their common action plan.

Prior to joining BCG, Johanna was an intern in the strategy departments of Disneyland Resort Paris, Star Alliance in Frankfurt, and L.E.K. in Paris.

AREAS OF EXPERTISE

EDUCATION

Master’s degree, ESCP-EAP European School of Management

Publications and Videos

What Will AI Do for Health Care?

Generative AI won’t replace the doctor-patient relationship. But it will make doctors—along with pharmaceutical companies, medtechs, and other health care organizations—even better at what they do.

How Can Health Care Be Socially Transformative?

BCG’s Johanna Benesty explains that, while businesses in every sector have the potential to be socially transformative, the opportunity in healthcare is particularly great.

How Public-Health Leaders Can Fight the Next Pandemic

COVID-19 offered valuable lessons in combating epidemic-level disease. Four measures can help institutionalize what we’ve learned.

Biopharma’s Role in Achieving Health Equity

Companies can take four steps to address the inequitable health outcomes that marginalized and underserved communities experience in the US.

Get the Right Therapies to the Right Patients with Next-Gen Analytics

To advance from promise to value, biopharma companies need to articulate and execute a bold vision for analytics as a fully scaled, continuously applied internal capability.

Winning the Fight Against Endemic COVID-19

COVID-19 will likely become endemic. If so, a global surveillance, treatment and vaccination infrastructure for monitoring and responding to outbreaks must be developed now.

Image of a Masked Woman Administering a Medical Vaccine into Someone's Arm

A Vaccination Strategy to Save Lives and Livelihoods

Protecting the health-vulnerable population first can shave months off a country’s reopening.

Sideways image of a people-moving conveyor belt with social distancing marks

Reimagining Global Health After the Coronavirus

What has worked, what can be improved, and what needs to be reimagined so that we are better prepared for the next pandemic and better able to improve health in the world’s poorest nations?

What Happens after We Develop a COVID-19 Vaccine?

BCG Managing Director & Partner Johanna Benesty looks at barriers to "equitable access"—making sure COVID-19 therapeutics are available to all—and shares a creative approach to vaccine research and development.

Image of a Hand Under a Faucet Running Water